Jihua Chen (Regeneron, NY, USA) author of ‘Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH’ published in Bioanalysis gives us an insight into his research and some of the major challenges in the field.
Browsing: anti-drug antibodies
Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH
It is documented that soluble drug targets in clinical study samples have generated false positive results in anti-drug antibody bridging assays due to target-mediated bridging. In this research paper read about strategies to mitigate target interference.
In this research article from Bioanalysis learn more about the immunogenicity of anti-body drug conjugates. The research follows eight molecules across 11 clinical trials to evaluate the potentially increased immunogenicity risk of these multi-domain biotherapeutics compared with monoclonal antibodies.
Author Montserrat Carrasco-Triguero (Genentech, CA, USA) gives us an insight into her research career and her paper published in Bioanalysis: Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials, in this author’s perspective feature.
Learn more about the positive impact of upfront systematic screening and characterization of conjugated critical reagent attributes on assay robustness in this methodology article in Bioanalysis.
Webinar available to view on demand. This webinar will give an overview of immunogenicity assay development, explore the impact of anti-drug antibodies on bioanalysis and review relevant case studies discussing in-study cut-point and tolerance.